---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-048738"
form_type: "8-K"
ticker: "RARE"
cik: "0001515673"
company_name: "Ultragenyx Pharmaceutical Inc."
filed_at: "2026-02-12T23:59:59+00:00"
generated_at: "2026-05-16T03:00:02.722468+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Ultragenyx Q4 rev $207M (+25%), net loss $129M; restructures 10% headcount; UX111 gets IRL

## Summary
- Full year 2025 total revenue $673M (+20% YoY); Crysvita $481M, Dojolvi $96M, Evkeeza $59M.
- Q4 net loss $129M ($1.29/share); full year net loss $575M ($5.83/share).
- Restructuring: 10% workforce cut (~130 employees), $50M charges; path to profitability in 2027.
- 2026 revenue guidance $730-760M; combined R&D+SG&A expenses flat to down low-single digits.
- UX111 BLA resubmitted; received Incomplete Response Letter requesting additional CMC documentation.

## SEC filing metadata
- accession: 0001193125-26-048738
- form_type: 8-K
- ticker: RARE
- cik: 0001515673
- company_name: Ultragenyx Pharmaceutical Inc.
- filed_at: 2026-02-12T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 2.05, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1515673/000119312526048738/0001193125-26-048738-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1515673/000119312526048738/rare-20260212.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-048738
- JSON: https://secwatch.observer/filing/0001193125-26-048738.json
- Plain text: https://secwatch.observer/filing/0001193125-26-048738.txt

## Source-grounded claims
- claim_id: fdc05aa556d3259e66215bd2195c09340ded7b72
  claim: Ultragenyx Pharmaceutical Inc. announced a restructuring with charges of approximately $50 million in total restructuring and restructuring-related charges affecting across the Company (10% workforce reduction of approximately 130 employees).
  evidence_excerpt: the Company is implementing a 10% workforce reduction of approximately 130 employees across the Company (the “RIF”). The Company began notifying affected employees on February 12, 2026, and expects this RIF to be substantially completed in the first half of 2026. The Company estimates that it will incur approximately $50 million in total restructuring and restructuring-related charges
  evidence_url: https://www.sec.gov/Archives/edgar/data/1515673/000119312526048738/0001193125-26-048738-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.